Research at Oslo University Hospital


Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.


Latest news

Findings regarding a novel non-genomic tamoxifen cytotoxic action published in ACS Chemical Biology

Theo Theodossiou<br>First author
Theo Theodossiou
First author

Theodossis (Theo) Theodossiou at the Department of Radiation Biology, in collaboration with two other departments at ICR and Department of Cellular Therapy (Authors: Theodossis Theodossiou, Sébastien Wälchli, Catherine Elisabeth Olsen, Ellen Skarpen and Kristian Berg), have published new research in ACS Chemical Biology regarding a novel non-genomic tamoxifen cytotoxic action. The results describe an alternative non-genomic utilization of tamoxifen that may be of clinical interest and describes also the mechanistic basis for this treatment effect. This non-genomic action could be of particular interest for estrogen receptor negative (or triple negative) cancers depending on their metabolic/redox physiology.


Tor Espen Thorvaldsen with cover story in Molecular Cancer Research


PhD student Tor Espen Thorvaldsen, together with postdoc Nina Marie Pedersen and their co-workers in Harald Stenmark's group at Institute for Cancer Research and Centre for Cancer Biomedicine, have published a cover story in the November 2015 issue of Molecular Cancer Research.


Ceremony Friday November 20th

Ragnar Mørk legacy prize 2015 to Guro E. Lind

From the ceremony:<br> Guro E. Lind and Harald A. Stenmark (photo Chema Bassols)
From the ceremony:
Guro E. Lind and Harald A. Stenmark (photo Chema Bassols)

The 2015 "Dr. Ragnar Mørk's legacy prize" went to Guro E. Lind, head of the Epigenetics Group at the Department of Molecular Oncology. This award of NOK 200.000 is annually given to scientists affiliated to the Norwegian Radium Hospital who have obtained important results within the field of cancer research. The ceremony took place on Friday November 20th in the Research Building at Montebello. Guro E. Lind gave a lecture about the research activities that has earned her the award.
Guro E. Lind receives Dr. Ragnar Mørk's prize for 2015 for her outstanding research on cancer epigenetics, which has led to identification of several novel biomarkers in colorectal cancer, bladder cancer, ovarian cancer,  lymphoma and cholangiocarcinoma. These biomarkers may form the basis for diagnostic tests for early detection of cancer.


Oslo University Hospital researchers receive 92 mill NOK from the Norwegian Cancer Society


The Norwegian Cancer Society has recently distributed in total 207 million NOK to Norwegian cancer researchers.

92 million went to scientists affiliated to Oslo University Hospital.

Image: Bjørn Erikstein (OUS), Anne Grethe Ryel (Norwegian Cancer Society) and Lisbeth Sommervoll (Ahus)
(Photo: Per Marius Didriksen)


The first-in-man Phase I clinical trial of the EpCAM-targeting immunotoxin MOC31PE

Yvonne Andersson
Yvonne Andersson

Yvonne Andersson and colleagues at the Department of Tumor Biology and Department of Oncology at OUS have performed the first-in-man Phase I clinical trial of the EpCAM-targeting immunotoxin (IT) MOC31PE.

The work - entitled “Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin” - is published in British Journal of Cancer.


Research on sonoactivatable nanoparticles funded by EuroNanoMed II ERA-NET program

Qian Peng
Qian Peng

Qian Peng at the Department of Pathology has received funding for 5,5 million NOK from the joint action of the Norwegian Research Council’s NANO2021 programme and ERA-NET platform that comprises 20 partners from 17 countries/regions through the European Commission’s 7th Framework Programme. The project, named SonoTherag, is coordinated by a French organization and Qian Peng together with Petras Juzenas is a partner in this project. This project has started in 2015 and will last until 2018.


Research on nanoparticle radiosensitizers funded by Euronanomed II ERA-NET program

Petras Juzenas
Petras Juzenas

Petras Juzenas, earlier from the Department of Radiation Biology, now at the Department of Pathology, has received funding from the joint action of the Norwegian Research Council’s NANO2021 programme and EuroNanoMed II ERA-NET platform. The project receives 1 million euros together with two collaborating academic partners from Belgium and France and two French commercial partners.
The project, named NanoBiT, will be coordinated by Petras Juzenas. This is the first time Norway is the coordinator of a Euronanomed (ERA-NET) project. This 3-year project starts in 2016.


PCI research funded by Euronanomed II ERA-NET program

Theodossis Theodossiou (left) and Kristian Berg
Theodossis Theodossiou (left) and Kristian Berg

Theodossis Theodossiou and Kristian Berg from the Photochemical internalisation (PCI) group at the Department of Radiation Biology have been funded by the Euronanomed II ERA-NET program. The project receives 1 million Euros together with 3 collaborating academic partners from Greece and France and one French commercial partner. The project, named PCInano, will be coordinated by Kristian Berg. This is the first time Norway is the coordinator of a Euronanomed (ERA-NET) project.


New gold-standard for miRNA annotations published in Annual Reviews of Genetics

Bastian Fromm<br>First author
Bastian Fromm
First author

Bastian Fromm and colleagues have developed a uniform system for the annotation and nomenclature of human miRNA genes. They have reviewed published miRNA predictions and found that only about one third of human “miRNAs” are supported as bona fide miRNA genes. Using this set of correct miRNAs, which is available online along with mouse, chicken and zebrafish sequences (, Fromm and coworkers from the Tumorbiology department together with international collaborators reconstructed human miRNA evolution and present a detailed analysis of sequential properties of human and vertebrate miRNAs. Altogether the work signifies an instrument for researchers that will help to distinguish miRNA gene derived sequences from other short RNAs or sequential noise and thus will improve the accuracy and import of miRNA studies.

The work is published with Annual Reviews of Genetics (journal impact factor 15.7).


Jahre lectures and award ceremony

OUS based award winners Ludvig Sollid and Kaisa Haglund

The Anders Jahre Senior Medical Prize for this year went to Professor Ludvig Sollid, University of Oslo, and Professor Rikard Holmdahl, Karolinska Institutet, Stockholm. The Anders Jahre Prize for Young Scientists went to Dr. Kaisa Haglund, Oslo University Hospital, and Professor Pernilla Lagergren, Karolinska Institutet, Stockholm.  The Jahre lectures took place on October 14th in Domus Medica. Here, the award winners gave lectures on their research, with free admission for everyone.

The award ceremony took place in the University Aula on October 15th from 18:00-19:00. University Rector Ole Petter Ottersen gave a speech, and there was an award ceremony and musical entertainment.